Journal of Cancer Therapy
Vol.5 No.1(2014), Paper ID 41644, 10
pages
DOI:10.4236/jct.2014.51004
Safety and Therapeutic Efficacy of the Lewis Y Carbohydrate Specific Humanized Antibody MB311 in Patients with Malignant Effusion
Thomas Bauernhofer, Helmut Samonigg, Peter Regitnik, Werner Weitzer, Brigitte Lileg, Günter Waxenecker, Susanne Wiederkum, Manuela Kainer, Manfred Schuster, Hans Loibner, Markus Fido, Ralf Kircheis, Andreas Nechansky
Medical University Graz, Graz, Austria
Medical University Graz, Graz, Austria
Medical University Graz, Graz, Austria
Medical University Graz, Graz, Austria
Medical University Graz, Graz, Austria
Igeneon, Vienna, Austria
Igeneon, Vienna, Austria
Igeneon, Vienna, Austria
Igeneon, Vienna, Austria
Igeneon, Vienna, Austria
Igeneon, Vienna, Austria
Igeneon, Vienna, Austria
Igeneon, Vienna, Austria
Copyright © 2014 Thomas Bauernhofer, Helmut Samonigg, Peter Regitnik, Werner Weitzer, Brigitte Lileg, Günter Waxenecker, Susanne Wiederkum, Manuela Kainer, Manfred Schuster, Hans Loibner, Markus Fido, Ralf Kircheis, Andreas Nechansky et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
T. Bauernhofer, H. Samonigg, P. Regitnik, W. Weitzer, B. Lileg, G. Waxenecker, S. Wiederkum, M. Kainer, M. Schuster, H. Loibner, M. Fido, R. Kircheis and A. Nechansky, "Safety and Therapeutic Efficacy of the Lewis Y Carbohydrate Specific Humanized Antibody MB311 in Patients with Malignant Effusion,"
Journal of Cancer Therapy, Vol. 5 No. 1, 2014, pp. 28-37. doi:
10.4236/jct.2014.51004.